Notoginsenoside R1 improves intestinal microvascular functioning in sepsis by targeting Drp1-mediated mitochondrial quality imbalance

Dongyao Hou,Ruixue Liu,Shuai Hao,Yong Dou,Guizhen Chen,Liangming Liu,Tao Li,Yunxing Cao,He Huang,Chenyang Duan
DOI: https://doi.org/10.1080/13880209.2024.2318349
2024-02-24
Pharmaceutical Biology
Abstract:Context Sepsis can result in critical organ failure, and notoginsenoside R1 (NGR1) offers mitochondrial protection.
pharmacology & pharmacy,medical laboratory technology,plant sciences
What problem does this paper attempt to address?
The paper aims to explore whether the main active component in Panax notoginseng saponins—Notoginsenoside R1 (NGR1)—can improve sepsis-induced small intestinal microvascular dysfunction by targeting the mitochondrial dynamics-related protein Drp1, thereby enhancing organ function and prognosis in sepsis patients. Specifically, the paper verifies this hypothesis through the following experimental methods: - **Animal Model**: Establishing a sepsis model using cecal ligation and puncture (CLP) in mice. - **Cell Model**: Simulating sepsis at the cellular level by stimulating primary mouse intestinal microvascular endothelial cells (IMVECs) with lipopolysaccharide (LPS). The research results show that NGR1 can inhibit Drp1-mediated mitochondrial quality imbalance, thereby preventing mitochondrial fragmentation, restoring the morphology and function of IMVECs, protecting intestinal barrier function, reducing vascular permeability, improving microcirculation flow, and ultimately enhancing the prognosis of sepsis. Therefore, the paper suggests that Drp1-mediated mitochondrial quality imbalance is a potential therapeutic target for sepsis, and small molecule natural drugs like NGR1 may provide new directions for organ protection after sepsis. Future research should focus on clinical trials to evaluate the efficacy of NGR1 in different patient populations, which may bring new breakthroughs in sepsis treatment.